Newsroom

LONDON--(BUSINESS WIRE)--  Re: Macquarie Group Limited USD 23,000,000.00 MATURING: 24-Aug-2027 ISIN: XS2525178047 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 24-Feb-2026 TO 26-May-2026 HAS BEEN FIXED AT 5.68 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 26-May-2026 WILL AMOUNT TO: USD 330,070.75 PER USD 23,000,000.00 DENOMINATION  ...

CIUDAD DE NUEVO TAIPÉI (Taiwán)--(BUSINESS WIRE)--El puente de Danjiang, uno de los proyectos de infraestructura pública más importantes de Taiwán en los últimos tiempos, se inauguró oficialmente con una serie de eventos públicos a gran escala, lo que transformó al puente en una nueva referencia cultural y espacio cívico. El programa incluyó el “Danjiang Bridge Together Arts Festival”, actividades públicas inmersivas y una presentación especial de Light Chain a cargo del Cloud Gate Dance Theatr...

LONDON--(BUSINESS WIRE)--  Re: Economic Master Issuer PLC GBP 500,000,000.00 MATURING: 25-Apr-2075 ISIN: XS3083792302 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 27-Apr-2026 TO 26-May-2026 HAS BEEN FIXED AT 4.21 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 26-May-2026 WILL AMOUNT TO: GBP 3.29 PER GBP 983.50 DENOMINATION  ...

LONDON--(BUSINESS WIRE)--  Re: SNB FUNDING LIMITED USD 25,000,000.00 MATURING: 26-Feb-2029 ISIN: XS3011719518 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 26-Feb-2026 TO 26-May-2026 HAS BEEN FIXED AT 4.70 PCT DAY BASIS: ACTUAL/360 INTEREST PAYABLE VALUE 26-May-2026 WILL AMOUNT TO: USD 11.63 PER USD 1,000.00 DENOMINATION  ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (the “Company”) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharmaceutical company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that its Combined General Meeting will be held tomorrow, Tuesday, May 19, 2026, at 2:00 p.m. CEST and will be broadcast live via the following link: GENSIGHT BIOLOGICS - Assembl...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (la « Société ») (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, annonce que son Assemblée Générale Mixte se tiendra demain, mardi 19 mai 2026 à 14h00 (heure de Paris), et sera retransmise en direct via le lien suivan...

LONDON--(BUSINESS WIRE)--Nearly 40% of global skin care sales are expected to take place online by 2030, as digital-first strategies and AI-driven discovery reshape beauty buying behaviour, according to market intelligence company Euromonitor International. Insights shared during the Euromonitor Live: First Look web event show how technology is transforming discovery and decision‑making, reshaping the beauty path to purchase. Citing the latest findings on beauty and personal care insights and t...

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), société de biotechnologie spécialisée dans le développement de plateformes technologiques dédiées à l’administration ciblée de thérapies innovantes (la « Société »), annonce avoir conclu une term-sheet engageante avec une société de biotechnologie opérant actuellement en mode furtif, définissant les principales modalités d’une collaboration et d’une licence exclusive mondiale. Les termes définitifs...

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targeted delivery of innovative therapies (the “Company”), announces that it has entered into a binding term-sheet with a biotech company currently operating in stealth mode, setting out the principal terms of a collaboration and exclusive worldwide license. The final terms remains subject to the signin...

LONDON--(BUSINESS WIRE)--  Re: WHITE ROSE MASTER ISSUER PLC GBP 350,000,000.00 MATURING: 16-Jul-2071 ISIN: XS3150740960 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 16-Apr-2026 TO 18-May-2026 HAS BEEN FIXED AT 4.22 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 18-May-2026 WILL AMOUNT TO: GBP 1,203,013.76 PER GBP 325,500,000.00 DENOMINATION  ...